RHOA G17V induces T follicular helper cell specification and involves angioimmunoblastic T-cell lymphoma via upregulating the expression of PON2 through an NF-κB-dependent mechanism

Oncoimmunology. 2022 Oct 11;11(1):2134536. doi: 10.1080/2162402X.2022.2134536. eCollection 2022.

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a malignant hematologic tumor arising from T follicular helper (Tfh) cells. High-throughput genomic sequencing studies have shown that AITL is characterized by a novel highly recurring somatic mutation in RHOA, encoding p.Gly17Val (RHOA G17V). However, the specific role of RHOA G17V in AITL remains unknown. Here, we demonstrated that expression of Rhoa G17V in CD4+ T cells increased cell proliferation and induces Tfh cell specification associated with Pon2 upregulation through an NF-κB-dependent mechanism. Further, loss of Pon2 attenuated oncogenic function induced by genetic lesions in Rhoa. In addition, an abnormality of RHOA G17V mutation and PON2 expression is also detected in patients with AITL. Our findings suggest that PON2 associated with RHOA G17V mutation might control the direction of the molecular agents-based AITL and provide a new therapeutic target in AITL.

Keywords: AITL; NF-κB pathway; PON2; RHOA; mutation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aryldialkylphosphatase / metabolism
  • Humans
  • Immunoblastic Lymphadenopathy* / genetics
  • Lymphoma, T-Cell* / genetics
  • Lymphoma, T-Cell* / metabolism
  • Lymphoma, T-Cell* / pathology
  • NF-kappa B / metabolism
  • Neoplasm Recurrence, Local
  • T Follicular Helper Cells
  • rhoA GTP-Binding Protein / genetics

Substances

  • NF-kappa B
  • RHOA protein, human
  • Aryldialkylphosphatase
  • PON2 protein, human
  • rhoA GTP-Binding Protein

Grants and funding

This work was supported by Natural Science Foundation of Guangdong Province (Grant No. 2019A1515011354).